Call Us : +603-9010-3058
Email Us : This email address is being protected from spambots. You need JavaScript enabled to view it.

You are here: Home Publications, News & Events News & Events

Sunday17 February 2019

Astro Awani : Second Interview with Dr. Hasumi

HITV is part of an international collaboration in the FDA clinical trial of HITV therapy in late stage cancer patients led by the University of Maryland, USA ( Project Name: "Autologous Dendritic Cells Derived From Peripheral Blood Mononuclear Cells Cultured with Granulocyte-Macrophage Colony-Stimulating Factor and Interleukin-4 ( CellGenix ); Administered Intratumoral" ).

The Human Initiated Therapeutic Vaccine, which was developed by Dr Kenichiro Hasumi, is an autologous (patient derived) active cell based immunotherapy for patients who are suffering from late stage or metastatic cancer. Dr Hasumi is the founder of Hasumi International Research Foundation ( www.hasumi-foundation.org )

Dr Hasumi's protocol has been found to be highly effective when used in combination with radiotherapy, and is a source of hope for cancer patients who already have metastases ( i.e the cancer has spread to other parts of the body ).

Asiaone : Hope for late-stage cancer patients


Patients demonstrated a complete response to the initial treatment, while some have remained disease-free. -NST

Wed, Oct 26, 2011. New Straits Times

KUALA LUMPUR - There is still hope for late-stage cancer patients as treatment that could help cure the disease is now available in the country.

The Human Initiated Therapeutic Vaccine (HITV) Therapy, previously available only in Japan, has been brought to Malaysia through the Mahameru International Medical Centre.

Dr Kenichiro Hasumi, founder and president of the Hasumi International Research Foundation, said HITV is an autologous (patient-derived) active cell-based immunotherapy.

Read more ...


HITV Lab is involved in cell-based biotechnology medical applications with special focus on Dendritic Cell-Based Immunotherapy for cancer. HITV Lab is committed to support an international collaboration in the FDA clinical trial of HITV Therapy in late-stage cancer patients led by the University of Maryland, USA.

FacebookTwitterGoogle Bookmarks